ECSP19056408A - Estrategia optimizada para modificaciones de omisión de exones mediante el uso de crispr/cas9 con secuencias guía triples - Google Patents
Estrategia optimizada para modificaciones de omisión de exones mediante el uso de crispr/cas9 con secuencias guía triplesInfo
- Publication number
- ECSP19056408A ECSP19056408A ECSENADI201956408A ECDI201956408A ECSP19056408A EC SP19056408 A ECSP19056408 A EC SP19056408A EC SENADI201956408 A ECSENADI201956408 A EC SENADI201956408A EC DI201956408 A ECDI201956408 A EC DI201956408A EC SP19056408 A ECSP19056408 A EC SP19056408A
- Authority
- EC
- Ecuador
- Prior art keywords
- cas9
- crispr
- modifications
- guide sequences
- dmd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
- C12N5/0659—Satellite cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/066—Tenocytes; Tendons, Ligaments
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0661—Smooth muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
Abstract
La edición genómica mediada por CRISPR/Cas9 tiene un potencial clínico para el tratamiento de enfermedades genéticas, como la distrofia muscular de Duchenne (DMD), que es causada por mutaciones en el gen de la distrofina. En la presente, mediante el uso de tres promotores para dirigir la expresión del mismo ARN guía de DMD, se logró una forma más sólida y segura de edición genómica en un modelo de ratón humanizado para DMD con una eliminación en el exón 50 y en un modelo de perro 916;Ex50-MD.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762442606P | 2017-01-05 | 2017-01-05 | |
US201762544449P | 2017-08-11 | 2017-08-11 | |
US201762596298P | 2017-12-08 | 2017-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19056408A true ECSP19056408A (es) | 2019-09-30 |
Family
ID=61193018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201956408A ECSP19056408A (es) | 2017-01-05 | 2019-08-06 | Estrategia optimizada para modificaciones de omisión de exones mediante el uso de crispr/cas9 con secuencias guía triples |
Country Status (21)
Country | Link |
---|---|
US (1) | US20190338311A1 (es) |
EP (1) | EP3565897A1 (es) |
JP (1) | JP2020503869A (es) |
KR (1) | KR102606174B1 (es) |
CN (1) | CN110506115A (es) |
AU (1) | AU2018205521A1 (es) |
BR (1) | BR112019013962A2 (es) |
CA (1) | CA3048635A1 (es) |
CL (1) | CL2019001882A1 (es) |
CO (1) | CO2019008181A2 (es) |
CR (1) | CR20190326A (es) |
DO (1) | DOP2019000179A (es) |
EC (1) | ECSP19056408A (es) |
IL (1) | IL267786A (es) |
JO (1) | JOP20190166A1 (es) |
MA (1) | MA47239A (es) |
MX (1) | MX2019008064A (es) |
PE (1) | PE20191357A1 (es) |
PH (1) | PH12019501561A1 (es) |
SG (1) | SG11201906147VA (es) |
WO (1) | WO2018129296A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
EP3362571A4 (en) | 2015-10-13 | 2019-07-10 | Duke University | GENOMIC ENGINEERING WITH TYPE I CRISPRISMS IN EUKARYOTIC CELLS |
KR20190134673A (ko) * | 2017-03-30 | 2019-12-04 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 게놈 편집에 의한 엑손 스키핑 유도 방법 |
WO2019136216A1 (en) * | 2018-01-05 | 2019-07-11 | The Board Of Regents Of The University Of Texas System | Therapeutic crispr/cas9 compositions and methods of use |
US20210261962A1 (en) * | 2018-06-21 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
JP2021532831A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
CA3108289A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
EP3896158A4 (en) * | 2018-12-11 | 2022-11-02 | Kyoto University | METHODS OF INDUCING A DELETION IN GENOMIC DNA |
WO2020142714A1 (en) * | 2019-01-04 | 2020-07-09 | Exonics Therapeutics, Inc. | Aav expression cassette and aav vectors comprising the same |
US10947534B2 (en) | 2019-03-07 | 2021-03-16 | The Trustees Of Columbia University In The City Of New York | RNA-guided DNA integration using Tn7-like transposons |
WO2020210776A1 (en) * | 2019-04-12 | 2020-10-15 | Duke University | Crispr/cas-based base editing composition for restoring dystrophin function |
EP3952925A4 (en) * | 2019-04-12 | 2024-01-24 | Univ California | COMPOSITIONS AND METHODS FOR MODIFYING DYSTROPHIN GENES |
WO2020225606A1 (en) | 2019-05-08 | 2020-11-12 | Crispr Therapeutics Ag | Crispr/cas all-in-two vector systems for treatment of dmd |
KR102264115B1 (ko) * | 2019-05-10 | 2021-06-14 | 한국과학기술연구원 | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 |
CN110499333A (zh) * | 2019-08-01 | 2019-11-26 | 广州德赫生物科技有限公司 | 用于修复dmd基因突变的核酸序列及系统 |
US20240091379A1 (en) * | 2019-10-11 | 2024-03-21 | Yale University | Compositions and methods for upregulating isoforms of dystrophin as therapy for duchenne muscular dystrophy (dmd) |
WO2021086083A2 (ko) * | 2019-10-29 | 2021-05-06 | 주식회사 진코어 | CRISPR/Cas12f1 시스템 효율화를 위한 엔지니어링 된 가이드 RNA 및 그 용도 |
CN111172191B (zh) * | 2020-02-21 | 2020-12-22 | 浙江大学 | 一种高效基因敲除载体及其应用 |
CN112063621B (zh) * | 2020-09-02 | 2022-06-28 | 西湖大学 | 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用 |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
WO2023159103A1 (en) * | 2022-02-17 | 2023-08-24 | The Board Of Regents Of The University Of Texas System | CRISPR/SpCas9 VARIANT AND METHODS FOR ENHANCED CORRECTON OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS |
KR20230134097A (ko) * | 2022-03-10 | 2023-09-20 | 주식회사 진코어 | Nhej 복구 경로 조절을 통해 핵산 세그먼트의 결실 효율을 증가시키기 위한 조성물 및 방법 |
CN115820642B (zh) * | 2022-11-11 | 2023-10-10 | 昆明理工大学 | 一种用于治疗杜氏肌营养不良症的CRISPR-Cas9系统 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE557094T1 (de) * | 2004-04-02 | 2012-05-15 | Univ Texas | Krebsspezifische promotoren |
PE20190843A1 (es) | 2012-05-25 | 2019-06-17 | Emmanuelle Charpentier | Arn de direccion a adn generico |
KR102551324B1 (ko) * | 2013-06-05 | 2023-07-05 | 듀크 유니버시티 | Rna-가이드 유전자 편집 및 유전자 조절 |
CA2942268A1 (en) * | 2014-03-12 | 2015-09-17 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
CN106714845A (zh) * | 2014-08-11 | 2017-05-24 | 得克萨斯州大学系统董事会 | 通过crispr/cas9介导的基因编辑预防肌营养不良 |
US20170266320A1 (en) * | 2014-12-01 | 2017-09-21 | President And Fellows Of Harvard College | RNA-Guided Systems for In Vivo Gene Editing |
CN107250364A (zh) * | 2015-01-16 | 2017-10-13 | 华盛顿大学 | 新的微小肌养蛋白及相关使用方法 |
ES2884838T3 (es) * | 2015-04-06 | 2021-12-13 | Univ Leland Stanford Junior | ARN guía químicamente modificados para la regulación génica mediada por CRISPR/CAS |
WO2016174056A1 (en) * | 2015-04-27 | 2016-11-03 | Genethon | Compositions and methods for the treatment of nucleotide repeat expansion disorders |
WO2017072590A1 (en) * | 2015-10-28 | 2017-05-04 | Crispr Therapeutics Ag | Materials and methods for treatment of duchenne muscular dystrophy |
EA201891317A3 (ru) * | 2015-11-30 | 2019-04-30 | Дьюк Юниверсити | Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения |
US20170362635A1 (en) | 2016-06-20 | 2017-12-21 | University Of Washington | Muscle-specific crispr/cas9 editing of genes |
-
2017
- 2017-06-16 JO JOP/2019/0166A patent/JOP20190166A1/ar unknown
-
2018
- 2018-01-05 SG SG11201906147VA patent/SG11201906147VA/en unknown
- 2018-01-05 KR KR1020197022753A patent/KR102606174B1/ko active IP Right Grant
- 2018-01-05 PE PE2019001384A patent/PE20191357A1/es unknown
- 2018-01-05 WO PCT/US2018/012558 patent/WO2018129296A1/en unknown
- 2018-01-05 MX MX2019008064A patent/MX2019008064A/es unknown
- 2018-01-05 BR BR112019013962-1A patent/BR112019013962A2/pt unknown
- 2018-01-05 JP JP2019536508A patent/JP2020503869A/ja active Pending
- 2018-01-05 MA MA047239A patent/MA47239A/fr unknown
- 2018-01-05 AU AU2018205521A patent/AU2018205521A1/en active Pending
- 2018-01-05 CA CA3048635A patent/CA3048635A1/en active Pending
- 2018-01-05 EP EP18704637.0A patent/EP3565897A1/en active Pending
- 2018-01-05 CR CR20190326A patent/CR20190326A/es unknown
- 2018-01-05 US US16/476,137 patent/US20190338311A1/en active Pending
- 2018-01-05 CN CN201880010288.7A patent/CN110506115A/zh active Pending
-
2019
- 2019-07-02 IL IL267786A patent/IL267786A/en unknown
- 2019-07-02 PH PH12019501561A patent/PH12019501561A1/en unknown
- 2019-07-05 DO DO2019000179A patent/DOP2019000179A/es unknown
- 2019-07-05 CL CL2019001882A patent/CL2019001882A1/es unknown
- 2019-07-29 CO CO2019008181A patent/CO2019008181A2/es unknown
- 2019-08-06 EC ECSENADI201956408A patent/ECSP19056408A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018205521A1 (en) | 2019-07-18 |
MA47239A (fr) | 2019-11-13 |
CN110506115A (zh) | 2019-11-26 |
PH12019501561A1 (en) | 2019-09-09 |
WO2018129296A1 (en) | 2018-07-12 |
KR20190100967A (ko) | 2019-08-29 |
IL267786A (en) | 2019-09-26 |
PE20191357A1 (es) | 2019-10-01 |
BR112019013962A2 (pt) | 2020-02-11 |
MX2019008064A (es) | 2020-07-20 |
EP3565897A1 (en) | 2019-11-13 |
JOP20190166A1 (ar) | 2019-07-02 |
US20190338311A1 (en) | 2019-11-07 |
CO2019008181A2 (es) | 2019-10-31 |
SG11201906147VA (en) | 2019-08-27 |
CR20190326A (es) | 2019-10-02 |
DOP2019000179A (es) | 2019-11-15 |
CA3048635A1 (en) | 2018-07-12 |
JP2020503869A (ja) | 2020-02-06 |
KR102606174B1 (ko) | 2023-11-27 |
CL2019001882A1 (es) | 2019-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19056408A (es) | Estrategia optimizada para modificaciones de omisión de exones mediante el uso de crispr/cas9 con secuencias guía triples | |
CO2017007335A2 (es) | Supresión del gen de la huntingtina inducida por la arni | |
PH12019500281A1 (en) | Regulation of gene expression using engineered nucleases | |
MX2021005226A (es) | Regulacion de expresion genica mediada por nucleasa. | |
IL250539A0 (en) | Nucleotides modified for nucleic acid synthesis, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes | |
MX2020012560A (es) | Metodos para tratar infecciones por el virus de filoviridae. | |
MY192848A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
MY176328A (en) | Targeted mutations | |
MX2018006116A (es) | Materiales y metodos para el tratamiento de miopatias basadas en titina y otras titinopatias. | |
EP4042298A4 (en) | QUANTUM COMPUTING-BASED HYBRID SOLUTION STRATEGIES FOR LARGE DISCRETE-CONTINUOUS OPTIMIZATION PROBLEMS | |
BR112015022522A2 (pt) | engenharia de genomas de planta usando sistemas crispr/cas | |
MX2022007933A (es) | Compuestos de polimetino y su uso como etiquetas fluorescentes. | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
PH12016502555A1 (en) | Methods of preparing substituted nucleotide analogs | |
CL2017000104A1 (es) | Compuestos novedosos de pirimidina sustituidos. | |
MY196912A (en) | Short pendant arm linkers for nucleotides in sequencing applications | |
GB2600568A8 (en) | Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing | |
MX2018005872A (es) | Profarmacos de acido nucleico. | |
MX366836B (es) | Celulas aviares para la produccion mejorada de virus. | |
MY182395A (en) | Recombinase mutants | |
BR112017015912A2 (pt) | reator de leito inclinado que permite utilizar uma pequena quantidade de catalisador | |
EA201991647A1 (ru) | ОПТИМИЗИРОВАННАЯ СТРАТЕГИЯ МОДИФИКАЦИЙ, ВЫЗЫВАЮЩИХ ПРОПУСК ЭКЗОНА, С ПРИМЕНЕНИЕМ CRISPR/Cas9 С ТРОЙНЫМИ НАПРАВЛЯЮЩИМИ ПОСЛЕДОВАТЕЛЬНОСТЯМИ | |
Ödman et al. | Data from: Distribution of label spacings for genome mapping in nanochannels | |
Rueppell et al. | Comparative genomic linkage mapping in Apis | |
RU2016147481A (ru) | Способ проведения ПЦР-ПДРФ для генотипирования крупного рогатого скота по гену β-LG |